What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
His primary areas of investigation include Internal medicine, Oncology, Surgery, Phases of clinical research and Crizotinib.
Internal medicine and Gastroenterology are frequently intertwined in his study.
His Oncology research incorporates elements of Adenocarcinoma, Tolerability and Regimen, Pathology.
His Surgery research includes themes of Neoadjuvant therapy, Cancer and Oxaliplatin, FOLFIRINOX.
His Phases of clinical research research includes elements of Prospective cohort study and Neutropenia.
His Crizotinib study integrates concerns from other disciplines, such as Anaplastic lymphoma kinase and Gene rearrangement.
His most cited work include:
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer (3607 citations)
- Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (1739 citations)
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer (1122 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Oncology, Surgery, Cancer and Colorectal cancer are his primary areas of study.
Internal medicine is often connected to Gastroenterology in his work.
He has researched Oncology in several fields, including Pathology, Radiation therapy and Adenocarcinoma.
His work in Surgery tackles topics such as Irinotecan which are related to areas like Oxaliplatin.
His studies in Colorectal cancer integrate themes in fields like Bevacizumab, Fluorouracil and Metastasis.
The study incorporates disciplines such as Cancer research, non-small cell lung cancer, Anaplastic lymphoma kinase, Exon and ROS1 in addition to Crizotinib.
He most often published in these fields:
- Internal medicine (58.25%)
- Oncology (42.25%)
- Surgery (19.00%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (58.25%)
- Oncology (42.25%)
- Colorectal cancer (17.00%)
In recent papers he was focusing on the following fields of study:
Jeffrey W. Clark mainly focuses on Internal medicine, Oncology, Colorectal cancer, Cancer and Cancer research.
Many of his studies involve connections with topics such as Gastroenterology and Internal medicine.
In his study, Perioperative is strongly linked to Circulating tumor DNA, which falls under the umbrella field of Oncology.
His Colorectal cancer research integrates issues from Locally advanced, Primary tumor and Nuclear medicine.
Jeffrey W. Clark works mostly in the field of Cancer, limiting it down to topics relating to Hazard ratio and, in certain cases, Odds ratio.
Nivolumab and Ipilimumab is closely connected to Phases of clinical research in his research, which is encompassed under the umbrella topic of Cancer research.
Between 2017 and 2021, his most popular works were:
- Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial (169 citations)
- Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. (116 citations)
- Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. (102 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
The scientist’s investigation covers issues in Internal medicine, Oncology, Crizotinib, Gastroenterology and Cancer research.
His studies in Hepatocellular carcinoma, Carcinoma, Oxaliplatin, Proportional hazards model and Hazard ratio are all subfields of Internal medicine research.
His Oncology research is multidisciplinary, incorporating elements of Colorectal cancer, Primary tumor, Targeted therapy and Mutational analysis.
His research in Crizotinib intersects with topics in ROS1, Chemotherapy and Exon.
Jeffrey W. Clark focuses mostly in the field of Gastroenterology, narrowing it down to topics relating to Radiation therapy and, in certain cases, Liver cancer and CD8.
His Cancer research study combines topics from a wide range of disciplines, such as Cancer, Nivolumab, Ipilimumab, Immunotherapy and Clone.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
